Cannabis drug on market

Cannabis has long been known to help ease pain in multiple sclerosis sufferers, and after 11 years in development the first cannabis-containing prescription drug has been released to the UK market.

 
Savitex is a new drug that contains extracts of cannabis

Sativex was developed by GW Pharmaceuticals – who have been growing cannabis at secret locations in England – and will be marketed by German company Bayer AG.

In June the UK Medicines and Healthcare product Regulatory Agency approved its use by as a treatment for spasticity – spasms, cramps and other similar symptoms – in multiple sclerosis patients who aren’t benefitting from other treatments. Its approval follows successful clinical trials and will cost the NHS around £11 per day for each patient.

Justin Gover, GW Pharmaceuticals’ managing director said: “Roughly one-third of multiple sclerosis patients are believed to have tried cannabis to get relief, with some surveys suggesting the proportion is as high as 43%.”

Bayer AG estimate that 100,000 people suffer from multiple sclerosis and that 11,500 people in the UK will be eligible for treatment with the drug, but only half will get a good response.

“The formal launch of Sativex represents a milestone in treating the disease,” said Pam Macfarlane, chief executive of the MS Trust, a charity which has campaigned for a licensed medicine derived from cannabis to be made available.

One Response to Cannabis drug on market

  1. Lynne Heal says:

    I have been refused SAVITEX and one lady from NHS telephoned to say NHS has no money to allow me to have it.I worked for NHS for a few years now I need help I cant get it.Doesnt make sense.I was also told NO ONE in uk will get CCSVI via NHS either.I have proof via two letters sent to me also.

Comment on this story

Labnews.co.uk is your website - so tell us what you think. Just complete the form below, and lets get the debate started!